Both ketamine and serotonergic psychedelics (SPs) have been studied as novel treatments for depression, particularly Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). Promising results and demonstrated benefits in preliminary research have garnered these compounds much attention. Noted for their rapidity of onset, as well as consistently observed reductions in depressive…


Previous articleMydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
Next articleDanish And British Startups Partner to Bring Innovative Psychedelics to Patients